Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.

Literature DB >> 14586685

Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.

Abstract

Calcimimetic agents are small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR). In parathyroid cells, they lower the threshold for receptor activation by extracellular calcium ions and diminish parathyroid hormone (PTH) secretion. Calcimimetic compounds thus represent a novel way of controlling excess PTH secretion in clinical disorders such as secondary hyperparathyroidism (SHPT) due to chronic renal failure. Clinical trials have documented that the calcimimetic agent cinacalcet hydrochloride effectively lowers plasma PTH levels without increasing serum calcium or phosphorus concentrations in adult hemodialysis patients with SHPT. Serum phosphorus levels and values for the calcium-phosphorus ion product in serum often decline as plasma PTH levels fall during treatment. Experimental evidence suggests that calcimimetic agents may also impede the development of parathyroid gland hyperplasia, an integral component of SHPT due to chronic renal failure. Calcimimetic agents have considerable potential, therefore, as part of new therapeutic strategies for SHPT.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2003 PMID： 14586685 DOI： 10.1007/s00467-003-1290-2

Source DB: PubMed Journal: Pediatr Nephrol ISSN： 0931-041X Impact factor: 3.714

26 in total

1. Recent developments in the management of secondary hyperparathyroidism.

Authors: W G Goodman
Journal: Kidney Int Date: 2001-03 Impact factor: 10.612

2. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

Authors: William G Goodman; Gerald A Hladik; Stewart A Turner; Peter W Blaisdell; David A Goodkin; Wei Liu; Yousri M Barri; Raphael M Cohen; Jack W Coburn
Journal: J Am Soc Nephrol Date: 2002-04 Impact factor: 10.121

3. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.

Authors: J Blacher; A P Guerin; B Pannier; S J Marchais; G M London
Journal: Hypertension Date: 2001-10 Impact factor: 10.190

4. Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy.

Authors: R W Chesney; A V Moorthy; J A Eisman; D K Jax; R B Mazess; H F DeLuca
Journal: N Engl J Med Date: 1978-02-02 Impact factor: 91.245

5. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.

Authors: Jill S Lindberg; Sharon M Moe; William G Goodman; Jack W Coburn; Stuart M Sprague; Wei Liu; Peter W Blaisdell; Robert M Brenner; Stewart A Turner; Kevin J Martin
Journal: Kidney Int Date: 2003-01 Impact factor: 10.612

6. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.

Authors: M Wada; N Nagano; Y Furuya; J Chin; E F Nemeth; J Fox
Journal: Kidney Int Date: 2000-01 Impact factor: 10.612

7. Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line.

Authors: T Yamaguchi; N Chattopadhyay; O Kifor; C Ye; P M Vassilev; J L Sanders; E M Brown
Journal: Am J Physiol Cell Physiol Date: 2001-02 Impact factor: 4.249

8. Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism.

Authors: E M Brown; A E Broadus; M F Brennan; D G Gardner; S J Marx; A M Spiegel; R W Downs; M Attie; G D Aurbach
Journal: J Clin Endocrinol Metab Date: 1979-04 Impact factor: 5.958

9. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.

Authors: M Wada; Y Furuya; J Sakiyama; N Kobayashi; S Miyata; H Ishii; N Nagano
Journal: J Clin Invest Date: 1997-12-15 Impact factor: 14.808

10. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.

Authors: J Silver; T Naveh-Many; H Mayer; H J Schmelzer; M M Popovtzer
Journal: J Clin Invest Date: 1986-11 Impact factor: 14.808

15 in total

Review 1. Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.

Authors: Greg L Plosker
Journal: Pharmacoeconomics Date: 2011-09 Impact factor: 4.981

2. Report of an NIH task force on research priorities in chronic kidney disease in children.

Authors: Russell W Chesney; Eileen Brewer; Marva Moxey-Mims; Sandra Watkins; Susan L Furth; William E Harmon; Richard N Fine; Ronald J Portman; Bradley A Warady; Isidro B Salusky; Craig B Langman; Debbie Gipson; Peter Scheidt; Harold Feldman; Frederick J Kaskel; Norman J Siegel
Journal: Pediatr Nephrol Date: 2005-10-27 Impact factor: 3.714

3. Calcimimetics--fooling the calcium receptor.

Authors: Eberhard Ritz
Journal: Pediatr Nephrol Date: 2004-10-27 Impact factor: 3.714

4. The effect of cinacalcet on intraoperative findings in tertiary hyperparathyroidism patients undergoing parathyroidectomy.

Authors: Yash R Somnay; Eric Weinlander; David F Schneider; Rebecca S Sippel; Herbert Chen
Journal: Surgery Date: 2014-11-11 Impact factor: 3.982

Review 5. Cinacalcet hydrochloride.

Authors: Julia A Barman Balfour; Lesley J Scott
Journal: Drugs Date: 2005 Impact factor: 9.546

Review 6. Use of calcimimetics in children with normal kidney function.

Authors: Judith Sebestyen VanSickle; Tarak Srivastava; Uri S Alon
Journal: Pediatr Nephrol Date: 2018-03-19 Impact factor: 3.714

7. Middle-term use of Cinacalcet in paediatric dialysis patients.

Authors: Caroline Platt; Carol Inward; Mary McGraw; Jan Dudley; Jane Tizard; Christine Burren; Moin A Saleem
Journal: Pediatr Nephrol Date: 2009-10-17 Impact factor: 3.714

8. Cinacalcet is efficacious in pediatric dialysis patients.

Authors: Douglas M Silverstein; Kanwal K Kher; Asha Moudgil; Mona Khurana; Jennifer Wilcox; Kathleen Moylan
Journal: Pediatr Nephrol Date: 2008-02-21 Impact factor: 3.714

9. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.

Authors: Takashi Shigematsu; Tadao Akizawa; Eiji Uchida; Yusuke Tsukamoto; Manabu Iwasaki; Shouzo Koshikawa
Journal: Am J Nephrol Date: 2008-09-17 Impact factor: 3.754

10. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.

Authors: Jutta Muscheites; Marianne Wigger; Erdmute Drueckler; Dagmar-Christiane Fischer; Guenther Kundt; Dieter Haffner
Journal: Pediatr Nephrol Date: 2008-05-27 Impact factor: 3.714